Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy and Sandoz, is a world leader in the research and development of products that protect and improve health and well-being.
Its core businesses are pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.
Novartis derives its name from the Latin words novae artes meaning "new skills." The term reflects the company's commitment to research and development that brings innovative new products to the communities it serves.
In 2009, the Novartis Group Companies achieved net sales of USD 44.3 billion and net income of USD 10.3 billion.
The Group, which invested USD 7.2 billion in research and development (R&D) employs approximately 96,700 people in 140 countries around the world, nearly a quarter of whom are based in the US.
Its global headquarters are located in Basel, Switzerland, and its US headquarters are in New Jersey.
Learn more about the Novartis US leadership team.
At the Novartis Institutes for BioMedical Research (NIBR), the goal is to discover new medicines regularly based on an understanding of molecular mechanisms of disease. NIBR scientists are exploring the intersection of the chemical and biological universes.
On March 7th, 1996, Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis.